samarium-153

samarium–153

A radiopharmaceutical used to treat bone pain caused by cancer metastases.
References in periodicals archive ?
The two new radioisotopes are rhenium-186 and samarium-153, Atomic Energy Organization of Iran Deputy Director Mohammad Qannadi said.
Radiologist Edward Silberstein of the University of Cincinnati Medical Center has been investigating a host of radionuclides with a natural affinity for bone, including samarium-153, strontium-89, and rhenium-186.
This device market encompasses devices for external beam radiation therapy (CyberKnife, Gamma Knife, electron emitting high energy linear accelerators, proton therapy machines etc), brachytherapy (seeds, applicators-afterloaders, and electronic brachytherapy) and systemic radiation therapy (Iodine-131, Samarium-153, Rhenium-186, Erbium-169, etc.
Percutaneous tumor curettage and interstitial delivery of samarium-153 coupled with kyphoplasty for treatment of vertebral metastases.
The study, "Use of Samarium-153 (QUADRAMET) to modulate phenotype and enhance killing of tumor cells" demonstrated that exposure to QUADRAMET resulted in up-regulation of surface molecules on cancer cells, including Fas (CD95), carcinoembryonic antigen (CEA), mucin 1 (MUC-1), intercellular adhesion molecule-1 (ICAM-1 or CD54), and major histocompatibility complex class I (MHC-1).
TABLE 38 SAMARIUM-153 RADIOISOTOPE MARKET REVENUE, BY GEOGRAPHY, 2009 - 2016 ($MILLION)
Bone marrow scan to assess functional reserve and predict severity and duration of neutropenia and thrombocytopenia following Samarium-153 therapy (Abstract 1795)"
Research findings presented in AACR abstract #4398 and in a poster titled "Use of Samarium-153 (QUADRAMET) to modulate phenotype and enhance killing of tumor cells," demonstrate that exposure to QUADRAMET resulted in up-regulation of five surface molecules on cancer cells, making it more likely that the cells will be identified and killed by tumor-specific cytotoxic T lymphocytes (CTLs).
during the Scientific Poster Session; -- "Treatment of painful bony metastases with samarium-153 lexidronam (QUADRAMET): a review" is scheduled to be presented on Sunday, June 19 from 6:45 p.
Market is segmented by Beta Emitters (Iodine-131 (I-131), Yttrium-90 (Y-90), Samarium-153 (SM-153), Rhenium-186 (RE-186), Lutetium-177 (LU-177)and Others) Alpha emitters(Radium-223 (RA-223) & Alpharadin, Actinium-225 (AC-225), Lead-212 (PB-212)/Bismuth-212 (BI-212)and Astatine-211 (AT-211)) and Brachytherapy (Cesium-131, Iodine-125, Palladium-103 and Iridium-192), by applications and by geography ( North America, Europe and Asia-Pacific).